Trials / Completed
CompletedNCT03001128
Biomarkers to Predict Time to Plasma HIV RNA Rebound
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 61 (actual)
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Network
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect information about what happens when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals. We will also study the safety of pausing ART under close observation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antiretroviral treatment pause | Antiretroviral treatment pause |
Timeline
- Start date
- 2017-02-23
- Primary completion
- 2021-01-29
- Completion
- 2021-01-29
- First posted
- 2016-12-22
- Last updated
- 2024-12-13
Locations
18 sites across 3 countries: United States, Puerto Rico, Thailand
Source: ClinicalTrials.gov record NCT03001128. Inclusion in this directory is not an endorsement.